TongliBio announces to receive an early investment from two private investment groups including TF capital

Time：2017-04-05

TongliBio announces to receive an early investment from two private investment groups including TF capital. The funds will support for IND submission to US FDA and CMC preparation of TL-010 API and tablets for cllinical developement, as well as ongoing preclinical-stage projects.

Previous： TongliBio announces TL-010 was granted with orphan drug designation by FDA

Next： TongliBio is invited to attend the WHO informal consultant meeting Sept.29-30. 2015 in Geneva, Switzerland

Email：tl.office@tonglibio.com
Telephone：86-0512-58113269
Company Address：Rm 401, Bldg D, No.1 North Guotai Rd, Zhangjiagang, Suzhou, Jiangsu Province, PRC
苏ICP备13010604号

Name*

Email*

Tel*

Content

Submit

Technical support: Three to Five Interconnection

TOP